Company news
Lyell Immunopharma, Inc. (NASDAQ:LYEL) news
Lyell Immunopharma, Inc. news releases on 6ix. Latest, Sep 14, 2026: Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
Press releases & updates
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
September 14, 2026
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
September 10, 2026
Lyell Immunopharma : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
August 6, 2026
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 25, 2026
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
June 12, 2026
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
June 8, 2026
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
June 3, 2026
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 1, 2026
Lyell Immunopharma Announces Participation in May Investor Conferences
May 12, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
May 6, 2026
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
March 12, 2026
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
March 9, 2026
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
March 8, 2026
Lyell Immunopharma Announces Participation in March Investor Conferences
February 22, 2026
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
February 12, 2026
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 7, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
November 12, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
November 11, 2025
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
November 10, 2025
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
November 3, 2025
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
September 3, 2025
Lyell Immunopharma Announces Participation in September Investor Conferences
September 2, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
August 12, 2025
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
July 25, 2025
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
June 23, 2025
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
June 17, 2025
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
June 9, 2025
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 4, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
May 13, 2025
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
May 1, 2025
Novavax Appoints Charles Newton to Board of Directors
April 29, 2025
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
April 15, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
March 11, 2025
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
February 18, 2025
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
January 8, 2025
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
December 8, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
November 6, 2024
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
November 4, 2024
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
October 30, 2024
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
October 23, 2024
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 3, 2024
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
September 23, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
August 6, 2024
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 25, 2024
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
May 6, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
May 5, 2024
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
March 4, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
February 27, 2024